AMRN — Amarin Corporation plc

Amarin Corporation (AMRN) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Revenue: $49.7 million, up 17% year-over-year.
• Net Product Revenue: $48.6 million, a 16% increase, driven by U.S. sales.
  • U.S. Revenue: $40.9 million, a 34% increase attributed to a change in customer mix and regained exclusivity with a large national pharmacy benefit manager (PBM).
  • European Revenue: $4.1 million, consistent with the prior year, reflecting the transition to Recordati.
  • Rest of World Revenue: $3.6 million, a decline from the previous year.
• Operating Loss: $11.1 million, significantly improved from a loss of $25.2 million in Q3 2024.
• Operating Margin: Negative 22%, improved from negative 60% in the prior year.
• Cash Position: $286.6 million in cash and investments, with no debt.

2. Strategic Updates and Business Highlights

• Transitioned to a fully partnered commercial model in international markets through a partnership with Recordati, covering nearly 100 markets.
• Focus on leveraging partnerships to expand VASCEPA's market presence, particularly in Europe where patent protection extends until 2039.
• Implemented a global restructuring to achieve $70 million in operational expense savings, with Q3 showing a 47% reduction in SG&A expenses.
• Continued strong presence in the U.S. market with over 50% share of the IPE market.

3. Forward Guidance and Outlook

• Anticipate continued growth in U.S. revenue, maintaining competitive pricing and exclusivity with major accounts through at least the end of 2025.
• Expect to achieve positive free cash flow in 2026, supported by improved operating margins and reduced expenses.
• Future milestone payments from Recordati will be based on sales performance, with confidence in their ability to drive growth.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue in Rest of World: Revenue halved compared to Q3 2024 due to variability in supply shipments and lack of major launches.
• European Revenue Transition: The transition to Recordati may temporarily impact revenue consistency, with expectations of variability in product revenue.
• Market Competition: Continued pressure from generic competitors and the need to maintain pricing strategies to defend market share.

5. Notable Q&A Insights

• U.S. Net Price Trajectory: Expected to remain stable through 2025, with potential declines in early 2026 due to negotiations with payers.
• Milestone Payments: Triggered by sales performance exceeding $100 million, with Recordati focused on prioritizing VASCEPA.
• Gross Margin Outlook: Anticipated decline in gross margin as the business shifts to a partnered model, but offset by reduced operating expenses leading to improved operating margins.
• Fenofibrate Update Impact: The FDA's revision of fenofibrate labeling could shift prescribing practices, potentially benefiting VASCEPA as providers and payers respond to updated scientific evidence.

Overall, Amarin is positioned for growth with strategic partnerships and operational efficiencies, despite facing challenges in international markets and competition.